BSE:500660

Stock Analysis Report

GlaxoSmithKline Pharmaceuticals

Executive Summary

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines worldwide.

Snowflake

Fundamentals

Flawless balance sheet with outstanding track record.


Similar Companies

Share Price & News

How has GlaxoSmithKline Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.5%

500660

4.0%

IN Pharmaceuticals

2.4%

IN Market


1 Year Return

10.0%

500660

-13.9%

IN Pharmaceuticals

8.0%

IN Market

Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned -13.9% over the past year.

Return vs Market: 500660 exceeded the Indian Market which returned 8% over the past year.


Shareholder returns

500660IndustryMarket
7 Day3.5%4.0%2.4%
30 Day7.0%-2.8%2.5%
90 Day23.5%0.7%3.6%
1 Year11.9%10.0%-13.1%-13.9%10.3%8.0%
3 Year5.3%1.0%-24.6%-26.2%22.3%16.0%
5 Year18.1%9.7%-10.2%-12.9%42.8%29.3%

Price Volatility Vs. Market

How volatile is GlaxoSmithKline Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

52.89x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 500660 (₹1482.7) is trading above our estimate of fair value (₹762.36)

Significantly Below Fair Value: 500660 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 500660 is poor value based on its PE Ratio (52.9x) compared to the Pharmaceuticals industry average (15.6x).

PE vs Market: 500660 is poor value based on its PE Ratio (52.9x) compared to the Indian market (13x).


Price to Earnings Growth Ratio

PEG Ratio: 500660 is poor value based on its PEG Ratio (37.3x)


Price to Book Ratio

PB vs Industry: 500660 is overvalued based on its PB Ratio (11.7x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

1.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 500660's forecast earnings growth (1.4% per year) is below the savings rate (7.6%).

Earnings vs Market: 500660's earnings (1.4% per year) are forecast to grow slower than the Indian market (18.4% per year).

High Growth Earnings: 500660's earnings are forecast to grow, but not significantly.

Revenue vs Market: 500660's revenue (13.8% per year) is forecast to grow faster than the Indian market (11.3% per year).

High Growth Revenue: 500660's revenue (13.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 500660's Return on Equity is forecast to be high in 3 years time (29.6%)


Next Steps

Past Performance

How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?

5.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 500660's earnings have grown by 5.1% per year over the past 5 years.

Accelerating Growth: 500660's earnings growth over the past year (26.9%) exceeds its 5-year average (5.1% per year).

Earnings vs Industry: 500660 earnings growth over the past year (26.9%) exceeded the Pharmaceuticals industry 14.2%.


Return on Equity

High ROE: 500660's Return on Equity (22.2%) is considered high.


Return on Assets

ROA vs Industry: 500660 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 500660 has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is GlaxoSmithKline Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 500660's short term assets (₹20.1B) exceeds its short term liabilities (₹14.5B)

Long Term Liabilities: 500660's short term assets (20.1B) exceeds its long term liabilities (3.2B)


Debt to Equity History and Analysis

Debt Level: 500660's debt to equity ratio (0.03%) is considered satisfactory

Reducing Debt: 500660's debt to equity ratio has reduced from 0.2% to 0.03% over the past 5 years.

Debt Coverage: 500660's debt is well covered by operating cash flow (68504%).

Interest Coverage: 500660 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: 500660 has a high level of physical assets or inventory.

Debt Coverage by Assets: 500660's debt is covered by short term assets (assets are 3446.761570x debt).


Next Steps

Dividend

What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?

1.35%

Current Dividend Yield


Dividend Yield vs Market

company1.3%marketbottom25%0.6%markettop25%2.4%industryaverage0.8%forecastin3Years1.7%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 500660's dividend (1.35%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 500660's dividend (1.35%) is low compared to the top 25% of dividend payers in the Indian market (2.41%).

Stable Dividend: 500660's dividend payments have been volatile in the past 10 years.

Growing Dividend: 500660's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (71.3%), 500660's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of GlaxoSmithKline Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Annaswamy Vaidheesh 0

4.2yrs

Tenure

₹77,985,000

Compensation

Mr. Annaswamy Vaidheesh has been Managing Director, Vice President of South Asia and Executive Director at GlaxoSmithkline Pharmaceuticals Limited since August 3, 2015. Mr. Vaidheesh serves as Director of  ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Annaswamy's total compensation is reasonable compared to companies of similar size in the Indian market.

Compensation vs Earnings: Annaswamy's compensation has increased by more than 20% in the past year.


Management Age and Tenure

2.3yrs

Average Tenure

Experienced Management: 500660's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

7.3yrs

Average Tenure

66yo

Average Age

Experienced Board: 500660's board of directors are considered experienced (7.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ajay Nadkarni

    VP of Administration & Real Estate and Company Secretary

    • Tenure: 0yrs
    • Compensation: ₹9.18m
  • Meenakshi Priyam

    Executive Vice President of Human Resources

    • Tenure: 1.9yrs
  • Puja Thakur (43yo)

    South Asia Finance Director

    • Tenure: 1.8yrs
    • Compensation: ₹23.62m
  • Raju Krishnaswamy (53yo)

    Executive Director of Technical

    • Tenure: 8.2yrs
    • Compensation: ₹26.00m
  • Sumer Dheri

    Executive Vice President of Vaccines

    • Tenure: 2.5yrs
  • Annaswamy Vaidheesh

    MD, VP of South Asia & Executive Director

    • Tenure: 4.2yrs
    • Compensation: ₹77.99m
  • Ransom D'Souza

    Vice President of Communications & Government Affairs

    • Tenure: 2.5yrs
  • Anil Iyer

    Chief Commercial Officer of Pharmaceuticals

    • Tenure: 2.1yrs
  • Nischal Hindia

    Executive Vice President of Legal & Corporate Affairs

    • Tenure: 0yrs
  • S. Balasubramanian

    Vice President of Ethics & Compliance

    • Tenure: 1yrs

Board Members

  • Nihal Vijaya Devadas Kaviratne (75yo)

    Non-Executive Independent Director

    • Tenure: 14.3yrs
    • Compensation: ₹2.20m
  • Anjali Bansal (48yo)

    Non-Executive Independent Director

    • Tenure: 6.7yrs
    • Compensation: ₹2.00m
  • Damodarannair Sundaram (66yo)

    Non-Executive Independent Director

    • Tenure: 10.3yrs
    • Compensation: ₹2.20m
  • Subesh Williams (57yo)

    Non Executive Director

    • Tenure: 2.5yrs
  • Pradeep Bhide (69yo)

    Non-Executive Independent Director

    • Tenure: 9yrs
    • Compensation: ₹2.10m
  • Puja Thakur (43yo)

    South Asia Finance Director

    • Tenure: 1.8yrs
    • Compensation: ₹23.62m
  • Raju Krishnaswamy (53yo)

    Executive Director of Technical

    • Tenure: 8.2yrs
    • Compensation: ₹26.00m
  • A. Roy (68yo)

    Non-Executive Independent Director

    • Tenure: 7.9yrs
    • Compensation: ₹2.00m
  • Annaswamy Vaidheesh

    MD, VP of South Asia & Executive Director

    • Tenure: 4.2yrs
    • Compensation: ₹77.99m
  • Renu Karnad (67yo)

    Independent Chairperson

    • Tenure: 0.5yrs

Company Information

GlaxoSmithKline Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Pharmaceuticals Limited
  • Ticker: 500660
  • Exchange: BSE
  • Founded: 1924
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹251.178b
  • Shares outstanding: 169.41m
  • Website: https://www.india-pharma.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Pharmaceuticals Limited
  • GSK House
  • Dr. Annie Besant Road
  • Mumbai
  • Maharashtra
  • 400030
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500660BSE (Mumbai Stock Exchange)YesEquity SharesININRJun 1996
GLAXONSEI (National Stock Exchange of India)YesEquity SharesININRJun 1996

Biography

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines worldwide. The company offers prescription and non-prescri ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 12:34
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.